Clinical trials: Natural Killer Cell Malignancies
Lymphoma, Extranodal NK-T-Cell
MESA Treatment for NK/T Cell Lymphoma
Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma
- Trial name
- MTN (NCT01933282)
- Testing
- MESA chemotherapy, MESA
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Air Force Military Medical University, China
High-risk Leukemias
"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"
Phase I / II study on infusion of alloreactive or stimulated Natural Killer cells with IL-15 ex vivo after haploidentical transplantation of hematopoietic progenitors in pediatric patients with hematologic malignancies (PHINK
- Trial name
- PHINK (NCT05304754)
- Testing
- NK cells stimulated ex vivo with IL-15, Alloreactive NK cells
- Where
- 10 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Advanced Melanoma, Metastatic Melanoma
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with…
- Trial name
- NCT05629546
- Testing
- Cytokine-induced memory-like natural killer cells, Relatilmab, Nivolumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01621477
- Testing
- clofarabine, cytarabine, busulfan
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
This phase I trial studies the side effects and best dose of COH06 with or without atezolizumab in patients with non-small cell lung cancer previously treated with PD-1 and/or PD-L1 immune checkpoint inhibitors that has spread to…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma
- Trial name
- NCT05334329
- Testing
- Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
AML, Adult
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
This is an open-label, Phase I study of QN-023a (allogeneic CAR-NK cells targeting CD33) in relapsed/refractory Acute Myeloid Leukemia (AML).
- Trial name
- NCT05665075
- Testing
- QN-023a, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Zhejiang University
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
MG4101 for Refractory or Relapsed AML
This study is a single center, single arm, open-labeled phase 2 clinical study. The aim of this study is to investigate the efficacy and safety of allogeneic natural killer cell (MG4101).
- Trial name
- NCT03349502
- Testing
- MG4101
- Where
- South Korea
- Volunteers
- 11 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
This Phase Ia study evaluated the safety and tolerability of a single escalating dose via intravenous infusion of the autologous invariant natural killer T cells (iNKT-cell) product GKL-006 in combination with transarterial…
- Trial name
- NCT07845266
- Testing
- GKL-006 Injection, transarterial chemoembolization
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Beijing Gene Key Life Technology Co., Ltd
Neoplasm Metastasis
Safety Study of Adoptive Transfer of Autologous IKDC-like Cells
The purpose of this study is to determine the safety of adoptive transferring autologous IKDC-like cells
- Trial name
- NCT02661685
- Testing
- autologous IKDC-like cells
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- National Defense Medical Center, Taiwan
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Colorectal Cancer, Surgery
Human Blood Specimen Collection to Evaluate Immune Cell Function
Natural killer (NK) cells are leukocytes of the innate immune system and play a central role in the control of cancer metastases.
- Conditions
- Colorectal Cancer, Surgery, Perioperative Care
- Trial name
- NCT03422120
- Testing
- Natural Killer Cell Activity Assay
- Where
- Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Non-small Cell Lung Cancer
Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer
Maintenance therapy has been considered as an important component to prolong survival in patients with advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01481259
- Testing
- Autologous cytokine-induced killer cell, Pemetrexed
- Where
- China
- Volunteers
- 120 people
- Sponsor
- People's Hospital of Guangxi Zhuang Autonomous Region
Non-small Cell Lung Cancer Metastatic
High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of non-small cell lung cancer.
- Trial name
- NCT03007875
- Testing
- high-activity natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma
To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma.
- Trial name
- HNJ-NKAES-2012 (NCT01944982)
- Testing
- Expanded haploidentical natural killer cells (NKAEs)
- Where
- Spain
- Volunteers
- 7 people
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Lymphoma
Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT
Evaluate the safety of natural killer (NK) cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation (SCT) from matched donors.
- Trial name
- NCT00586690
- Testing
- NK Cell infusion using CD56 monoclonal antibody, Donor Apheresis
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- David Rizzieri, MD
Acute Myeloid Leukemia
Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.
- Trial name
- NCT05334693
- Testing
- Expanded haploidentical NK cells
- Where
- Belarus
- Volunteers
- 15 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
T-Cell Lymphoma, Lymphoma, Non-Hodgkin's
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
Primary Objective: To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (C-CHOP) in…
- Trial name
- NCT00161590
- Testing
- CHOP and alemtuzumab
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University